



ERRATUM

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

William G. Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J. Hauske, Jyothis T. George, Jennifer B. Green, Martin J. Landray, Colin Baigent and Christoph Wanner

Clinical Kidney Journal, Volume 11, Issue 6, 1 December 2018, Pages 749–761, <https://doi.org/10.1093/ckj/sfy090>

In the footnote of Figure 5 “Empagliflozin 0/4687 vs placebo 1/2333 participant reported Fournier’s gangrene (perineal necrotizing fasciitis)” has been replaced with “Empagliflozin 0/4687 vs placebo 0/2333 participants reported Fournier’s gangrene (perineal necrotizing fasciitis)”.